Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of international research on androgen deprivation therapy (ADT) for prostate cancer ...

ADT with injectable gonadotropin-releasing hormone (GnRH) receptor agonists such as leuprolide has been associated with cardiovascular morbidity, and cardiovascular disease is the leading cause of ...

ADT-associated cardiovascular risk may be partly mediated by accelerated coronary atherosclerosis. Plaque progression is more pronounced with the GnRH agonist leuprolide compared with the GnRH ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...